311 related articles for article (PubMed ID: 29499330)
1. Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer.
Birnbaum DJ; Bertucci F; Finetti P; Birnbaum D; Mamessier E
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):248-255. PubMed ID: 29499330
[TBL] [Abstract][Full Text] [Related]
2. Speeding towards individualized treatment for pancreatic cancer by taking an alternative road.
Iovanna J; Dusetti N
Cancer Lett; 2017 Dec; 410():63-67. PubMed ID: 28947138
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
Zhao L; Zhao H; Yan H
BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
[TBL] [Abstract][Full Text] [Related]
4. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.
Frank TS; Sun X; Zhang Y; Yang J; Fisher WE; Gingras MC; Li M
Cancer Lett; 2015 Jul; 363(1):1-6. PubMed ID: 25890222
[TBL] [Abstract][Full Text] [Related]
5. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
Front Immunol; 2021; 12():690056. PubMed ID: 34335594
[TBL] [Abstract][Full Text] [Related]
6. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
8. Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma.
Neuzillet C; Tijeras-Raballand A; Ragulan C; Cros J; Patil Y; Martinet M; Erkan M; Kleeff J; Wilson J; Apte M; Tosolini M; Wilson AS; Delvecchio FR; Bousquet C; Paradis V; Hammel P; Sadanandam A; Kocher HM
J Pathol; 2019 May; 248(1):51-65. PubMed ID: 30575030
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling of morphologic subtypes of pancreatic ductal adenocarcinoma using surgical and EUS-FNB specimens.
Rasmussen LG; Verbeke CS; Sørensen MD; Pfeiffer P; Tan Q; Mortensen MB; Fristrup C; Detlefsen S
Pancreatology; 2021 Apr; 21(3):530-543. PubMed ID: 33637450
[TBL] [Abstract][Full Text] [Related]
10. Pancreas Cancer Precision Treatment Using Avatar Mice from a Bioinformatics Perspective.
Perales-Patón J; Piñeiro-Yañez E; Tejero H; López-Casas PP; Hidalgo M; Gómez-López G; Al-Shahrour F
Public Health Genomics; 2017; 20(2):81-91. PubMed ID: 28858862
[TBL] [Abstract][Full Text] [Related]
11. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers.
Singhi AD; George B; Greenbowe JR; Chung J; Suh J; Maitra A; Klempner SJ; Hendifar A; Milind JM; Golan T; Brand RE; Zureikat AH; Roy S; Schrock AB; Miller VA; Ross JS; Ali SM; Bahary N
Gastroenterology; 2019 Jun; 156(8):2242-2253.e4. PubMed ID: 30836094
[TBL] [Abstract][Full Text] [Related]
12. Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches.
Sahin IH; Lowery MA; Stadler ZK; Salo-Mullen E; Iacobuzio-Donahue CA; Kelsen DP; O'Reilly EM
Expert Rev Gastroenterol Hepatol; 2016 Aug; 10(8):893-905. PubMed ID: 26881472
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer.
Pishvaian MJ; Brody JR
Oncology (Williston Park); 2017 Mar; 31(3):159-66, 168. PubMed ID: 28299752
[TBL] [Abstract][Full Text] [Related]
14. Molecular subtypes of pancreatic cancer based on miRNA expression profiles have independent prognostic value.
Namkung J; Kwon W; Choi Y; Yi SG; Han S; Kang MJ; Kim SW; Park T; Jang JY
J Gastroenterol Hepatol; 2016 Jun; 31(6):1160-7. PubMed ID: 26644397
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic cancer subtypes: a roadmap for precision medicine.
Torres C; Grippo PJ
Ann Med; 2018 Jun; 50(4):277-287. PubMed ID: 29537309
[TBL] [Abstract][Full Text] [Related]
16. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
[TBL] [Abstract][Full Text] [Related]
17. Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases.
Connor AA; Denroche RE; Jang GH; Lemire M; Zhang A; Chan-Seng-Yue M; Wilson G; Grant RC; Merico D; Lungu I; Bartlett JMS; Chadwick D; Liang SB; Eagles J; Mbabaali F; Miller JK; Krzyzanowski P; Armstrong H; Luo X; Jorgensen LGT; Romero JM; Bavi P; Fischer SE; Serra S; Hafezi-Bakhtiari S; Caglar D; Roehrl MHA; Cleary S; Hollingsworth MA; Petersen GM; Thayer S; Law CHL; Nanji S; Golan T; Smith AL; Borgida A; Dodd A; Hedley D; Wouters BG; O'Kane GM; Wilson JM; Zogopoulos G; Notta F; Knox JJ; Gallinger S
Cancer Cell; 2019 Feb; 35(2):267-282.e7. PubMed ID: 30686769
[TBL] [Abstract][Full Text] [Related]
18. Genomics of pancreatic ductal adenocarcinoma.
Pilarsky C; Grutzmann R
Hepatobiliary Pancreat Dis Int; 2014 Aug; 13(4):381-5. PubMed ID: 25100122
[TBL] [Abstract][Full Text] [Related]
19. Molecular Alterations Associated with DNA Repair in Pancreatic Adenocarcinoma Are Associated with Sites of Recurrence.
Ferguson MD; Dong L; Wan J; Deneve JL; Dickson PV; Behrman SW; Shibata D; Martin MG; Glazer ES
J Gastrointest Cancer; 2019 Jun; 50(2):285-291. PubMed ID: 29427136
[TBL] [Abstract][Full Text] [Related]
20. Genetics of Familial and Sporadic Pancreatic Cancer.
Wood LD; Yurgelun MB; Goggins MG
Gastroenterology; 2019 May; 156(7):2041-2055. PubMed ID: 30660730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
